Cepharanthine - Sairiyo Therapeutics
Alternative Names: PD-001 - Sairiyo Therapeutics; PD001Latest Information Update: 21 May 2024
At a glance
- Originator Sairiyo Therapeutics
- Class Alkaloids; Anti-infectives; Anti-inflammatories; Antineoplastics; Antivirals; Nonsteroidal anti-inflammatories
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Infections
Most Recent Events
- 15 May 2024 Sairiyo Therapeutics anticipates Clinical Trial Application approval from Australian Human Research Ethics Committee, regarding initiation of a phase I trial for Cancer and Infections in Australia, in June 2024
- 15 May 2024 Sairiyo Therapeutics submits Clinical Trial Application for a phase I trial for Cancer and Infections, to Australian Human Research Ethics Committee, for approval
- 15 May 2024 Sairiyo Therapeutics plans a phase II trial for Cancer and Infections in USA